Navigation Links
Corgenix Reports New Clinical Data Correlating AtherOx Technology,With Vascular Disease

that increased AtherOx levels were found in coronary patients with more severe disease as judged by cardiac catheterization, and correlated with adverse outcomes or complications such as new angioplasty, stent replacement, failure of coronary artery bypass grafts, heart attacks, strokes and even cardiovascular death. Luis Lopez, MD, Corgenix' Chief Medical Officer said "Interestingly, data from this study suggests the combined presence of both AtherOx complexes and anti-phospholipid antibodies could infer an increased risk for vascular complications in coronary artery disease patients."

Douglass Simpson, Corgenix' President and Chief Executive Officer said, "We are pleased to see this exciting new data on the AtherOx technology. We believe this unique science targets a significant worldwide clinical need, and we look forward to seeing additional data over the next year, leading to the opportunity to bring these products to the market. As new clinical findings continue to validate the utility of AtherOx and anti-AtherOx, we anticipate this technology has the potential to become an important addition to medical care worldwide."

"These findings indicate important relationships between AtherOx and the severity of cardiovascular disease," added Dr. Lopez. "We hope to have the ability to match patients with a treatment that may improve their survival, and if borne out in the ongoing clinical studies now undergoing analysis, could fulfill the promise of reducing the incidence of cardiovascular disease."

About AtherOx(TM)

The AtherOx technology utilizes oxidized low-density-lipoprotein (oxLDL) complexed with the plasma protein B2GPI. Although oxLDL has been implicated in cardiovascular disease, clinical data demonstrates that the determination of AtherOx, rather than oxLDL alone, is more predictive of the risk of progressive atherosclerotic cardiovascular disease. Corgenix licensed this technology in 2002, and is developing several products util
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
2. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
3. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
4. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
5. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
6. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
7. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
8. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
9. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
10. Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia
11. Bentley Reports Positive Results with Nasulin Intranasal Insulin Spray at the American Diabetes Association Meeting
Post Your Comments:
(Date:9/18/2014)... YORK and PLAINSBORO, N.J. ... announced today its support of the National Hemophilia ... Care , which provides support to people with ... physical and psychosocial challenges that can impede disease ... six modules, Communication With Your Provider About ...
(Date:9/18/2014)... 18, 2014 After 6 months of ... finally here - the new programme for the next Cool ... of our global Cool Chain series, has just been released! ... As the lines between supply chain, logistics, QA ... programme that is broad and yet specific, focused and yet ...
(Date:9/18/2014)... 18, 2014   Regulus Therapeutics Inc . ... leading the discovery and development of innovative medicines ... ATHENA natural history of disease study in patients ... with no approved therapy. The ATHENA study is ... function markers such as Glomerular Filtration Rate ("GFR"), ...
Breaking Medicine Technology:Novo Nordisk Supports National Hemophilia Foundation Initiative for "Collaborating in Care" Disease Management Program 2Novo Nordisk Supports National Hemophilia Foundation Initiative for "Collaborating in Care" Disease Management Program 3Europe's Biggest and Longest-Running Gathering of Life Sciences Logistics, Supply Chain & QA Professionals 2Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 2Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 3Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 4Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 5Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 6
... March 31, 2011 Watson Pharmaceuticals, Inc. (NYSE: ... is initiating launch activities of Nulecit™ (sodium ferric ... of GeneraMedix Inc.,s, Abbreviated New Drug Application (ANDA). ... alternative to Sanofi-Aventis, Ferrlecit ® .  In July ...
... DIEGO, March 31, 2011 OncoSec Medical Inc. (OTC BB: ... tumor cancers, announced today that it has raised more than ... to three institutional investors. OncoSec issued 1,456,000 units at a ... Each unit consisted of one share of common stock and ...
Cached Medicine Technology:Watson Announces Approval of Nulecit™, the First Generic Alternative to Ferrlecit® for the Treatment of Iron Deficiency Anemia 2Watson Announces Approval of Nulecit™, the First Generic Alternative to Ferrlecit® for the Treatment of Iron Deficiency Anemia 3Watson Announces Approval of Nulecit™, the First Generic Alternative to Ferrlecit® for the Treatment of Iron Deficiency Anemia 4OncoSec Medical Closes $1.1M Financing 2
(Date:9/18/2014)... Springs, FL (PRWEB) September 18, 2014 It ... and run, sprint or walk for healthier and happier kids. ... support and participate in the 4th Annual Miami Children’s Hospital ... Wheels. http://www.hyundaihopeonwheels.org , The 5K will ... finishing location will be outside of Coral Gables City Hall ...
(Date:9/18/2014)... Johannesburg, South Africa (PRWEB) September 18, 2014 ... organization to adopt the HABIT™ Program in ... by Indaba Health and Wellness, and distributed in South ... version of the HABIT program, which has been tailored ... , IHW HABIT™ focuses on behavior modification and chronic ...
(Date:9/18/2014)... . Two ... ,International Space Station Research Competition, with their project ,Egypt ... will see the International Space Station crew perform experiments ... proteins of the hepatitis C virus under microgravity conditions. ... Station is scheduled to lift off from Cape Canaveral ...
(Date:9/18/2014)... 18, 2014 PlatinumCode, a leading ... collection products for the healthcare industry, announced earlier ... five percent of their profits of the sale ... In making the announcement, PlatinumCode has launched various ... providing clinical and hospital labs with their popular ...
(Date:9/18/2014)... 2014 T-System Inc. today announced ... documentation system — EV™ for physicians ... assessing several best-of-breed solutions, Holyoke chose T-System’s solution ... physician productivity and reimbursement, but also its ability ... still be used to capture emergency department, (ED) ...
Breaking Medicine News(10 mins):Health News:South Florida Hyundai Dealers Association Proudly Support the 4th Annual Miami Children’s Hospital 5K Run/Walk this Saturday August 20th in Coral Gables 2Health News:South Florida Hyundai Dealers Association Proudly Support the 4th Annual Miami Children’s Hospital 5K Run/Walk this Saturday August 20th in Coral Gables 3Health News:Hepatitis C virus proteins in space 2Health News:PlatinumCode Commits to Donating Five Percent of Profits from the sale of Pink Products to Support Breast Cancer Awareness 2Health News:Holyoke Medical Center ER Improves Productivity and Reimbursement with T-System 2
... active participation in their communities has led researchers to define this ... now be considered a distinct retirement role, according to an article ... (Volume 48, Number 3). , The authors identify civic ... one day per week that directly impact the local community. ...
... 6 hours for participants in phase II trial ... gout drug called pegloticase lowered levels of uric acid ... hours in most patients. , That,s the conclusion of ... and Savient Pharmaceuticals, the company that,s developing the drug. ...
... Ill., Sept. 3 Z Trim Holdings,Inc. (Amex: ... 2, 2008, the Company,entered into private placement subscription ... of convertible notes and warrants, for an,aggregate offering ... a,"Unit" and collectively, the "Units") consists of a ...
... 28,000 ratings and comments are overwhelmingly positive, ... of,Regence members would recommend their doctor to others, ... member Web site -- myRegence.com. A,"Member Feedback" feature ... on their experiences with individual providers, including,physicians, dentists, ...
... (doi:10.1016/j.clim.2008.06.009) published in Clinical Immunology, the official ... new method enabling the detection of multiple parameters of ... specific blood cells from an individual with type 1 ... play in the development of the disease and during ...
... on earnings and productivity for healthcare professionals in the United States, ... decrease in patient loads. , ... New York, NY ... focusing on earnings and productivity for physicians in America features some ...
Cached Medicine News:Health News:Experts establish baseline for civic engagement among retirees 2Health News:New Drug Helps Relieve Gout 2Health News:Z Trim Holdings, Inc. Announces Private Placement Funding 2Health News:Z Trim Holdings, Inc. Announces Private Placement Funding 3Health News:Doctors Get High Marks as Regence Members Share Opinions Online 2Health News:Fresh Medical Industry News Reveals Earnings & Productivity Changes For Physicians 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: